Promising Phase 2B Clinical Trial Results for Galapagos’ Filgotinib in Rheumatoid Arthritis Treatment
News, rheumatoid arthritis
The biotechnology company Galapagos NV recently announced in a press release the results of the DARWIN 1 Phase 2B trial, an ongoing 24 week placebo-controlled, double-blind study to assess the efficacy ... Read more